To manufacture and distribute Tenofovir Alafenamide (TAF) based HIV treatments
Strides Arcolab announced that it has entered into a licensing agreement with Gilead Sciences, Inc. under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs.As per the licensing agreement, pending US Food & Drug Administration approval of the Gilead product, Strides will receive a technology transfer from Gilead, enabling Strides to manufacture low cost version of TAF for developing countries.
The license being granted to Strides extends to 112 countries, which together account for more than 30 million people living with HIV.
Powered by Capital Market - Live News
